CC-90002
Drug
Celgene Corporation
Total Payments
$2.1M
Transactions
39
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $304,814 | 17 | 8 |
| 2018 | $707,094 | 12 | 0 |
| 2017 | $1.0M | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 39 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-90002-ST-001 | Celgene Corporation | $640,591 | 0 |
| CC-90002-ST-001 - A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers | Celgene Corporation | $442,368 | 0 |
| CC-90002-AML-001 | Celgene Corporation | $406,992 | 0 |
| CC-90002-AML-001 - A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects with Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome | Celgene Corporation | $264,726 | 0 |
| A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers (CC-90002-ST-001) | Celgene Corporation | $197,683 | 3 |
| A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects with Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome (CC-90002-AML-001) | Celgene Corporation | $107,131 | 5 |
Top Doctors Receiving Payments for CC-90002
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Scottsdale, AZ | $2.1M | 31 |
| , M.D | Internal Medicine | New Haven, CT | $476.00 | 1 |
| Wendy Stock | Hematology & Oncology | Burr Ridge, IL | $476.00 | 1 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $476.00 | 1 |
| , M.D | Hematology & Oncology | Tucson, AZ | $476.00 | 1 |
| , MD | Medical Oncology | Philadelphia, PA | $476.00 | 1 |
| , MD | Hematology | Chicago, IL | $476.00 | 1 |
| , M.D.,PH.D | Hematology & Oncology | Boston, MA | $476.00 | 1 |
| , M.D | Internal Medicine | Los Angeles, CA | $476.00 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $2.1M
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 8
- Transactions 39
About CC-90002
CC-90002 is a drug associated with $2.1M in payments to 8 healthcare providers, recorded across 39 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $304,814 was paid across 17 transactions to 8 doctors.
The most common payment nature for CC-90002 is "Unspecified" ($2.1M, 100.0% of total).
CC-90002 is associated with 6 research studies, including "CC-90002-ST-001" ($640,591).